BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

8 articles for AJ Olson

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.EBI
The Scripps Research Institute
Discovery of protein phosphatase 2C inhibitors by virtual screening.EBI
Rockefeller University
Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors.EBI
The Scripps Research Institute
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.EBI
Universita Di Napoli "Federico Ii
Tyrosine kinase inhibitor and uses thereofBDB
Xuanzhu Pharma
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBDB
Boehringer Ingelheim International
Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.BDB
Chemical Diversity Research Institute
Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.BDB
Saarland University